About

Pharnext

An advanced clinical-stage biopharmaceutical company
Our company

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.

Our vision

We strive to address serious unmet medical needs, with the ambition to bring safe, effective therapies to market. We believe that diseases require solutions mastering their complexity by combining therapeutics in a synergistic/additive way.

Our mission

We are working hard to finalize the clinical development of PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), and bring it to market as soon as possible through an agreement with a pharmaceutical company.

Our product

PXT3003, Pharnext's most advanced drug candidate, is in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating, inherited peripheral neuropathy that affects hundreds of thousands of patients worldwide on a daily basis. PXT3003 was discovered using Pharnext's proprietary R&D approach (Pleotherapy™). An international pivotal Phase III study of PXT3003, the PREMIER trial, enrolling 387 CMT1A patients was completed in August 2023.

Pharnext is a limited partnership with shares (S.C.A.). Pharnext Développement, a company controlled and managed by Neovacs, is its general partner and manager

Leadership team
Hugo Brugière, MSc
Hugo Brugière, MSc
Pharnext Développement Representative, Manager
Vincent Serra
Vincent Serra
Chief Operating Officer and Chief Scientific Officer
Gilbert Wagener, MD, PhD
Gilbert Wagener, MD, PhD
Chief Medical Officer
Raj Thota, MSc
Raj Thota, MSc
Chief Manufacturing Officer and Head of CMC
Melissa Israel, BSc
Melissa Israel, BSc
VP, Clinical Operations
Abhijit Pangu, MPharm
Abhijit Pangu, MPharm
Head of Regulatory Affairs
Scott Johnson, BSc
Scott Johnson, BSc
VP, Head of Quality
Members of Supervisory Board
Joshua Schafer
Joshua Schafer
Lawrence Steinman
Lawrence Steinman
James Kuo
James Kuo
Guy-Charles Fanneau de La Horie
Guy-Charles Fanneau de La Horie

Timeline

Explore our history since inception in 2007

2Q07
2Q07
Pharnext is founded by Prof. Daniel Cohen and collaborators

2Q07
4Q10
PXT3003: Launch of Phase 2 clinical trials in CMT1A

2Q07
1Q13
PXT864: Launch of Phase 2 clinical trials in Alzheimer’s disease

2Q07
2Q14
PXT3003: EMA and FDA orphan drug designation for CMT1A

2Q07
4Q14
PXT3003: Positive Phase 2 results in CMT1A

2Q07
4Q15
PXT3003: Launch of Phase 3 clinical trials in CMT1A

2Q07
3Q16
Pharnext IPO on Alternext Stock Exchange in Paris

2Q07
1Q17
R&D agreement with Galapagos to generate a new pipeline of synergistic drug combinations

2Q07
2Q17
Strategic partnership with Tasly, a leading Chinese pharmaceutical group

2Q07
4Q18
Pharnext and Vitaccess launch International CMT&Me Observational Study

2Q07
4Q18
PXT3003: Positive topline results from pivotal Phase 3 trial in CMT1A

2Q07
1Q19
PXT3003: FDA Fast Track designation for the treatment of CMT1A

2Q07
1Q20
PXT3003: Encouraging preliminary data from open-label Phase 3 extension study in CMT1A

2Q07
1Q20
PXT3003 granted “Promising Innovative Medicine” status by UK MHRA in CMT1A

2Q07
1Q21
Launch of the PREMIER trial, Pivotal Phase 3 clinical study, in CMT1A

Pipeline